Targets › LRRK2
4 programs from 4 companies in 6 trials: 5 Phase 2, 1 Phase 3; Neurology; next expected readout Mar 2027.
Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking. Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation. (UniProt, Q5S007)
Open in Phaseline: the race on LRRK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Remternetug (LY3372993) LRRK2 inhibitor | LRRK2 | Phase 3 | Alzheimer's Disease; Alzheimers Disease | Apr 2029 |
| Denali Therapeutics | BIIB122 LRRK2 kinase inhibitor | LRRK2 | Phase 2 | Parkinson Disease | Mar 2027 |
| Neuron23 | NEU-411 LRRK2 inhibitor | LRRK2 | Phase 2 | Parkinson Disease | Dec 2027 |
| Syntara | PXS-4728A LRRK2 inhibitor | LRRK2 | Phase 2 | REM Sleep Behavior Disorder | – |
Parkinson Disease (2) Alzheimers Disease (2) REM Sleep Behavior Disorder (1) Alzheimer's Disease (1)
small molecule (3), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.